News
|
Careers
|
Contact Us
About Vanda
Development Pipeline
Discovery Research
Investor Relations
meet vanda
We are using pharmacogenetics to match promising molecules
to the right patients. So selecting the right medicine will be
easier, thanks to our more personal approach.
June 26, 2008
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
June 5, 2008
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
May 22, 2008
Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
May 8, 2008
Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
Read More in the Newsroom
Iloperidone
VEC-162
VSF-173